Novartis Pharmaceuticals Canada Inc. et al. v. Pharmascience Inc.
2022
T-2582-22
Pending
New PM(NOC) Regulations
Action under the new Patented Medicines (Notice of Compliance) Regulations regarding Patent No. 2,472,399, 2,590,511 and 2,703,598 (sacubitril/valsartan)
Counsel to:
Pharmascience Inc.
The decision is reported
here.
Meet the team

Warren Sprigings
Partner

Mingquan Zhang, Ph.D.
Associate

Nathaniel Dillonsmith
Associate
.jpg)
David Reive
Partner